Dasi S, Naab T, Kwabi-Addo B, Apprey V, Beyene D, Dewitty Jr R
Cancer Genomics Proteomics. 2025; 22(2):208-230.
PMID: 39993808
PMC: 11880923.
DOI: 10.21873/cgp.20497.
Yang X, Yang D, Qi X, Luo X, Zhang G
Front Oncol. 2025; 14():1467033.
PMID: 39845328
PMC: 11753220.
DOI: 10.3389/fonc.2024.1467033.
Guclu-Geyik F, Erginel T, Gulec C, Koseoglu-Buyukkaya P, Erginel-Unaltuna N
Mol Biol Rep. 2024; 51(1):1144.
PMID: 39531130
DOI: 10.1007/s11033-024-10091-w.
Capatina A, Malcolm J, Stenning J, Moore R, Bridge K, Brackenbury W
Front Cell Dev Biol. 2024; 12:1421629.
PMID: 39282472
PMC: 11392762.
DOI: 10.3389/fcell.2024.1421629.
Hall K, Filardo E
Cells. 2023; 12(20).
PMID: 37887304
PMC: 10605794.
DOI: 10.3390/cells12202460.
Methylation of promoter induced by SNAI2-DNMT3B complex promotes epithelial-mesenchymal transition and correlates with poor prognosis in ERα-positive breast cancers.
Li J, Deng Q, Zhu J, Min W, Hu X, Yu Chen H
MedComm (2020). 2023; 4(6):e403.
PMID: 37881785
PMC: 10594044.
DOI: 10.1002/mco2.403.
Therapeutic resistance to anti-oestrogen therapy in breast cancer.
Will M, Liang J, Metcalfe C, Chandarlapaty S
Nat Rev Cancer. 2023; 23(10):673-685.
PMID: 37500767
PMC: 10529099.
DOI: 10.1038/s41568-023-00604-3.
MOF negatively regulates estrogen receptor α signaling CUL4B-mediated protein degradation in breast cancer.
Zhang X, Yang Y, Li D, Wu Z, Liu H, Zhao Z
Front Oncol. 2022; 12:868866.
PMID: 36212422
PMC: 9539768.
DOI: 10.3389/fonc.2022.868866.
Endocrine therapy resistance: what we know and future directions.
Musheyev D, Alayev A
Explor Target Antitumor Ther. 2022; 3(4):480-496.
PMID: 36071983
PMC: 9446423.
DOI: 10.37349/etat.2022.00096.
Estrogen Receptor and Vascular Aging.
Davezac M, Buscato M, Zahreddine R, Lacolley P, Henrion D, Lenfant F
Front Aging. 2022; 2:727380.
PMID: 35821994
PMC: 9261451.
DOI: 10.3389/fragi.2021.727380.
Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer.
Xuan Thang N, Yoo S, La H, Lee H, Park C, Park K
Biomedicines. 2022; 10(4).
PMID: 35453496
PMC: 9031900.
DOI: 10.3390/biomedicines10040748.
Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers GSK3 Inhibition.
Sharma V, Joshi J, Yeh I, Doughman Y, Blankenberg D, Wald D
Front Oncol. 2022; 12:824594.
PMID: 35402240
PMC: 8988137.
DOI: 10.3389/fonc.2022.824594.
Tamoxifen and oxidative stress: an overlooked connection.
Ahmed N, Samec M, Liskova A, Kubatka P, Saso L
Discov Oncol. 2022; 12(1):17.
PMID: 35201439
PMC: 8777555.
DOI: 10.1007/s12672-021-00411-y.
Epigenetic Therapies and Biomarkers in Breast Cancer.
Brown L, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C, Lim E
Cancers (Basel). 2022; 14(3).
PMID: 35158742
PMC: 8833457.
DOI: 10.3390/cancers14030474.
Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells.
Santos-Martinez N, Diaz L, Ortiz-Ortega V, Ordaz-Rosado D, Prado-Garcia H, Avila E
Am J Cancer Res. 2022; 11(12):5951-5964.
PMID: 35018235
PMC: 8727803.
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O, Huynh-Dam K, Sahin O
J Mol Med (Berl). 2021; 99(12):1691-1710.
PMID: 34623477
PMC: 8611518.
DOI: 10.1007/s00109-021-02136-5.
DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation.
Batra R, Lifshitz A, Tufegdzic Vidakovic A, Chin S, Sati-Batra A, Sammut S
Nat Commun. 2021; 12(1):5406.
PMID: 34518533
PMC: 8437946.
DOI: 10.1038/s41467-021-25661-w.
Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials.
Padayachee J, Singh M
Nanobiomedicine (Rij). 2021; 7:1849543520983196.
PMID: 33488814
PMC: 7768851.
DOI: 10.1177/1849543520983196.
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.
Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G
Cells. 2020; 9(12).
PMID: 33316954
PMC: 7764472.
DOI: 10.3390/cells9122644.
Epigenetic Mechanisms in Canine Cancer.
Xavier P, Muller S, Fukumasu H
Front Oncol. 2020; 10:591843.
PMID: 33194754
PMC: 7646326.
DOI: 10.3389/fonc.2020.591843.